Table 2.
Vaccines side effects of the study population.
| BNT162b2 | mRNA-1273 | ChAdOx1n CoV-19 | JNJ-78436735 | Adjusted p value * | Overall | |
|---|---|---|---|---|---|---|
| Arm pain (%) | ||||||
| Any | 5131 (75·1%) | 3283 (83·8%) | 346 (63·0%) | 1706 (67·2%) | < 0·0001† | 10,466 (75·6%) |
| Mild | 3515 (51·5%) | 1844 (47·1%) | 284 (51·7%) | 1404 (55·3%) | 7047 (50·9%) | |
| Moderate | 1455 (21·3%) | 1196 (30·5%) | 56 (10·2%) | 278 (10·9%) | 2985 (21·6%) | |
| Severe | 161 (2·4%) | 243 (6·2%) | 6 (1·1%) | 24 (0·9%) | 434 (3·1%) | |
| Headache (%) | ||||||
| Any | 1752 (25·6%) | 1253 (32·0%) | 241 (43·9%) | 1190 (46·9%) | < 0·0001† | 4436 (32·1%) |
| Mild | 1247 (18·3%) | 826 (21·1%) | 158 (28·8%) | 719 (28·3%) | 2950 (21·3%) | |
| Moderate | 402 (5·9%) | 319 (8·1%) | 63 (11·5%) | 322 (12·7%) | 1106 (8·0%) | |
| Severe | 103 (1·5%) | 108 (2·8%) | 20 (3·6%) | 149 (5·9%) | 380 (2·7%) | |
| Muscle pain (%) | ||||||
| Any | 1766 (25·9%) | 1223 (31·2%) | 275 (50·1%) | 1239 (48·8%) | < 0·0001† | 4503 (32·5%) |
| Mild | 1291 (18·9%) | 778 (19·9%) | 161 (29·3%) | 625 (24·6%) | 2855 (20·6%) | |
| Moderate | 376 (5·5%) | 318 (8·1%) | 79 (14·4%) | 409 (16·1%) | 1182 (8·5%) | |
| Severe | 99 (1·4%) | 127 (3·2%) | 35 (6·4%) | 205 (8·1%) | 466 (3·4%) | |
| Fever (%) | ||||||
| Any | 754 (11·0%) | 780 (19·9%) | 175 (31·9%) | 960 (37·8%) | < 0·0001† | 2669 (19·3%) |
| Mild | 603 (8·8%) | 494 (12·6%) | 109 (19·9%) | 544 (21·4%) | 1750 (12·6%) | |
| Moderate | 124 (1·8%) | 200 (5·1%) | 47 (8·6%) | 305 (12·0%) | 676 (4·9%) | |
| Severe | 27 (0·4%) | 86 (2·2%) | 19 (3·5%) | 111 (4·4%) | 243 (1·8%) | |
| Tiredness (%) | ||||||
| Any | 3094 (45·3%) | 2120 (54·1%) | 354 (64·5%) | 1743 (68·6%) | < 0·0001† | 7311 (52·8%) |
| Mild | 2105 (30·8%) | 1283 (32·7%) | 192 (35·0%) | 887 (34·9%) | 4467 (32·3%) | |
| Moderate | 721 (10·6%) | 542 (13·8%) | 116 (21·1%) | 501 (19·7%) | 1880 (13·6%) | |
| Severe | 268 (3·9%) | 295 (7·5%) | 46 (8·4%) | 355 (14·0%) | 964 (7·0%) | |
| Cutaneous eruptions (%) | ||||||
| Any | 279 (4·1%) | 236 (6·0%) | 26 (4·7%) | 133 (5·2%) | 0·0002† | 674 (4·9%) |
| Mild | 222 (3·2%) | 156 (4·0%) | 23 (4·2%) | 97 (3·8%) | 498 (3·6%) | |
| Moderate | 41 (0·6%) | 54 (1·4%) | 1 (0·2%) | 21 (0·8%) | 117 (0·8%) | |
| Severe | 16 (0·2%) | 26 (0·7%) | 2 (0·4%) | 15 (0·6%) | 59 (0·4%) | |
| Loss of appetite (%) | ||||||
| 474 (6·9%) | 434 (11·1%) | 82 (14·9%) | 388 (15·3%) | < 0·0001† | 1378 (10·0%) | |
| Nausea/vomiting (%) | ||||||
| 362 (5·3%) | 332 (8·5%) | 51 (9·3%) | 240 (9·5%) | < 0·0001† | 985 (7·1%) | |
| Facial paralysis (%) | ||||||
| 25 (0·4%) | 18 (0·5%) | 4 (0·7%) | 10 (0·4%) | 1·0000 | 57 (0·4%) | |
All percentages are presented as column-wise calculations. * p values from χ2 tests, for accounting proportions differences, have been adjusted using Holm’s method. † Significant difference among groups at α = 0.01.